Two Secrets Behind a Dietitian Marketplace Worth $1 Billion

01 /The Concept

Nutrition apps are a crowded graveyard. Most of them launch, spike briefly on New Year's resolution traffic, and fade. Nourish has done something different: it's profitable, and it just raised $70 million at a valuation above $1 billion.

The model is a dietitian marketplace. Users find a registered dietitian who fits their insurance plan, covers their specific health concern, and has availability – then book recurring video sessions to work on their nutrition goals.

Those goals vary: managing chronic digestive issues, reducing cholesterol, following a diabetes-specific protocol, sports nutrition, healthy aging. After an initial intake session to establish a baseline and build a plan, patients and dietitians meet regularly to track progress, adjust the protocol, and address questions.

Between sessions, users can message their dietitian directly in the app, revisit session notes, read health content, and use the app as a goal tracker. AI is being layered in to handle routine questions between human sessions.

There's also a recipe section and the ability to order meal kit delivery or groceries directly through the app – a revenue stream via affiliate commissions.

The clinical outcomes are strong: 91% of users report feeling better. 57% report reduced stomach pain and discomfort. 23% lowered their cholesterol. 25% established consistent eating habits within their first 30 days.

Nourish graduated from Y Combinator in late 2021 and has since served 150,000 users across a network of 2,500+ dietitians. Notably, 94% of users pay nothing out of pocket – their care is covered by health insurance, which pays Nourish directly. The startup raised $8 million in early 2023, then $35 million in spring 2024, and now $70 million – a steadily accelerating trajectory.

02 /Why It Matters

The obvious question for any nutrition app is retention: why would someone stay engaged long enough for the business to work? Motivation to eat healthy tends to flare up and burn out quickly.

Nourish's answer is to avoid that population entirely. The app doesn't target people who want to eat better – it targets people who have chronic conditions that require them to manage their diet continuously. Not as a choice, but as a medical necessity.

This is also why the insurance relationship works so cleanly. Insurers spend enormous sums treating complications from poorly managed chronic conditions. Dietary support that prevents or reduces those complications saves them money – making Nourish a cost-reduction tool in their vocabulary, not a lifestyle product.

And the market is large: nearly 60% of Americans have at least one chronic condition. In 1995, that was 118 million people. By 2010, 141 million. By 2030, projections put it at 171 million.

There's one pointed objection to address: GLP-1 drugs like Ozempic, originally developed for diabetes, are now everywhere as weight-loss tools. If you can take a drug to manage weight and metabolic health, why bother with dietary counseling?

Recent research suggests the combination is actually superior to either alone. Patients who pair GLP-1 treatment with structured nutrition support lose 33% more weight. Proper nutrition also counteracts some of the drugs' side effects – notably muscle mass loss. And after stopping the medication, dietary habits are what sustain the results and prevent rebound – saving patients significant money over time.

In short, Nourish didn't pick the right product. It picked the right audience – people who can't opt out.

03 /Opportunities

Health is a vast and permanent market. Startups keep entering it and keep failing, usually for the same pair of reasons.

Appeals to healthy living don't work as a retention strategy. You can spark interest – but you can't sustain it. The only audience that sticks with health apps indefinitely is people who have no choice: those managing chronic conditions that require ongoing attention.

The second failure mode is the payer problem: most people don't pay for preventive health until they're in an ambulance. Before and after a health crisis, the motivation is weak. The smarter move is to get paid by someone who thinks rationally about money – like an insurer calculating how much cheaper it is to support a patient's lifestyle than to treat their complications.

Nourish isn't the only company to see this. Sempre Health ([related review](/review/napominalka-na-45-millionov-dollarov)) raised $45.5 million for a medication adherence app that reminds chronic-condition patients to refill and take their prescriptions on time, with pharmaceutical manufacturers funding the discounts that motivate behavior. Elfie ([related review](/review/dlja-3-milliardov-chelovek-na-vsju-zhizn)) raised $5 million for a healthy-habits tracker that rewards adherence with discounts on medications and health services, targeting the same global population of 3 billion people living with chronic conditions.

If you want to build in health, choose chronic patients as your audience and insurers or pharma as your payer. Nourish's billion-dollar valuation is the clearest evidence yet that this formula works.